BioCorRx Reports Business Update for the Third Quarter of 2023
PremiumPress ReleasesBioCorRx Reports Business Update for the Third Quarter of 2023
9M ago
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
PremiumPress Releases
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
12M ago
BioCorRx Reports Business Update for the Second Quarter of 2023
PremiumPress Releases
BioCorRx Reports Business Update for the Second Quarter of 2023
12M ago
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
PremiumPress ReleasesBioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
1y ago
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
PremiumPress Releases
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
2y ago
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
PremiumPress Releases
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100